1. Background {#sec1}
=============

Genetic variations in regions that encode apolipoproteins, including apoE, apoJ, apoC-III, and apoA-I, are associated with Alzheimer\'s disease (AD) [@bib1], [@bib2], [@bib3], [@bib4]. The relationships between plasma concentrations of apolipoproteins and AD have been difficult to disentangle [@bib5]. Most evidence suggests that plasma apoE levels are inversely associated with AD incidence [@bib5], and one study suggests that plasma apoC-III levels are lower in prevalent AD [@bib6].

The relationship between apolipoproteins and AD is complicated by the fact that apolipoproteins can reside on both low-density lipoproteins and high-density lipoproteins (HDLs), two lipoprotein classes that seem to differ in their associations with AD [@bib7]. Beyond its major structural protein component apoA-I, HDL hosts dozens of associated proteins [@bib8]. In the brain, lipoproteins are only found in the density range similar to HDL and contain primarily apoE and some apoA-I [@bib9]. By identifying apolipoproteins that do and do not go together, subspecies of apolipoproteins can be determined. It is possible that in the presence or absence of, for example, apoJ, plasma concentrations of apoE in HDL may show a stronger association with AD pathophysiology. In previous work, we reported that concentrations of some apolipoproteins in cerebrospinal fluid (CSF) are better reflected by measures of apolipoprotein subspecies in plasma than with the corresponding total plasma concentrations [@bib10]. This supports the significance of studying apolipoprotein subspeciation in plasma in relation to brain structure and function.

To this end, we investigated the associations of plasma apolipoproteins and their subspecies with brain ß-amyloid deposition, hippocampal volume, and white matter lesion volumes.

2. Methods {#sec2}
==========

2.1. Study population and design {#sec2.1}
--------------------------------

Ginkgo Evaluation of Memory Study (GEMS) was a multicenter, double-blinded, placebo-controlled, randomized clinical trial ([Clinicaltrials.gov](http://Clinicaltrials.gov){#intref0010} identifier: [NCT00010803](NCT00010803){#intref0015}) to evaluate the effect of Ginkgo biloba for the prevention of dementia in older adults. The design and selection criteria have been described previously [@bib11]. Briefly, 3069 community-dwelling men and women aged 72--96 years with normal cognition or mild cognitive impairment (MCI) were recruited between 2000 and 2002 and followed up for an average of 6 years. The screening visit included the administration of a neuropsychological test battery by trained technicians, assessment of vital signs and medical history including diabetes mellitus, and blood sample collection. Participants were reevaluated at subsequent semiannual clinic visits through August 2004 and annual follow-up visits through 2008.

The present study was performed in a subsample of 197 participants from the Pittsburgh site recruited into the GEMS Imaging Study who remained dementia free throughout the GEMS trial. These participants were invited to have Pittsburgh Compound B (PiB) positron emission tomography (PET) brain scans and structural magnetic resonance imaging scans of the brain in 2009, approximately 10 ± 3 months after GEMS closeout. Three participants were excluded for technical problems with PiB PET, three were excluded who developed dementia between 2008 and imaging, and 15 participants did not have an adequate blood sample taken at the time of PET scanning; thus, 176 participants were eligible for this analysis. Written informed consent was obtained from study participants and their proxies, and the study was approved by the Human Use Subcommittee of the Radioactive Drug Research Committee and the Institutional Review Board of the University of Pittsburgh.

2.2. Biochemical measurements {#sec2.2}
-----------------------------

Participants underwent phlebotomy at the screening visit and at study closeout in 2008. Frozen plasma samples, stored at the GEMS blood repository at the National Cell Repository for AD in Indiana, were shipped on dry ice to the lipid laboratory of the Harvard T. H. Chan School of Public Health for biochemical measurements.

We conducted two related sets of apolipoprotein measurements. First, we measured total levels of four apolipoproteins, namely, apoJ, apoE, apoA-I, and apoC-III, in whole plasma using sandwich enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN; and Academy Biomedical Company Inc, Houston, TX).

Second, to focus on apolipoproteins in the HDL fraction of plasma, we removed apoB-containing lipoproteins by dextran sulfate and magnesium chloride precipitation. Within the non-apoB fraction, concentrations of apoE, apoA-I, and apoC-III were measured using sandwich enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN; and Academy Biomedical Company Inc., Houston, TX). For measurement of apoA-I and apoE subspecies defined on coexisting apolipoproteins of interest in the non-apoB fraction, a patented modified sandwich enzyme-linked immunosorbent assay was used. For example, for measurement of apoE containing apoJ, 96-well plates were coated with anti-apoJ antibody. Diluted samples were incubated on these plates to bind lipoproteins containing apoJ. The fraction bound to this plate was released by dissociation of the lipoprotein complex with Tween-containing diluent (1 × PBS/2% BSA/0.05% Tween 20) and transferred to a second plate coated with anti-apoE antibody to quantify the concentration of apoE containing apoJ. The concentration of apoE that was not associated with apoJ was calculated as the difference of the measured total apoE concentration minus the measured concentration of apoE containing apoJ. Together, this approach provided concentrations of apoE containing apoJ and the concentration of apoE lacking apoJ ([Fig. 1](#fig1){ref-type="fig"}), as well as their sum of total apoE concentration. Both samples from baseline (2000 to 2002) and 2008 from an individual were assayed together on the same 96-well plate. HDL cholesterol was isolated for measurement by dextran sulfate/magnesium chloride precipitation of apoB-containing lipoproteins, and the resulting supernatant, total plasma cholesterol, and plasma triglycerides were measured by enzymatic assay (Thermo Fisher Scientific, Waltham, MA). Overall, the average coefficients of variation were below 20% for all apolipoproteins and apolipoprotein subspecies ([Supplementary Table A.2](#appsec1){ref-type="sec"}). Samples were measured in 11 batches. Each batch contains four plasma pool samples, composed of the plasma from between 4 and 9 people depending on the pool. These pools were measured for each analyte for more than 20 times to produce an expected value. The data on each plate were adjusted using a correction factor that was the slope of the line formed by regressing the obtained values of the four control samples against their expected values.Fig. 1Measurement of apolipoproteins and apolipoprotein subspecies. Here, apoE in HDL containing or lacking apoJ was measured by a modified sandwich enzyme-linked immunosorbent assay approach (values are means). When measuring any apolipoprotein subspecies in the HDL fraction of plasma, apoB-containing lipoproteins are first removed. Abbreviations: HDLs, high-density lipoproteins; apo, apolipoproteins.

2.3. Neuroimaging {#sec2.3}
-----------------

ß-Amyloid plaque deposition was quantified by using PiB PET scanning as published previously [@bib12]. PET images were acquired in four 5-minute frames starting 50 minutes after injection of ^11^C-labeled PiB ligand (15 ± 1.5 mCi) using an ECAT HR + scanner (Siemens/CTI Modular Imaging, Knoxville, Tennessee) in 3D mode (63 planes; slide with 2.4 mm) equipped with a Neuro-Insert (CTI PET Systems, Knoxville, Tennessee). The PET data were reconstructed to 6 mm transverse and axial image resolution using Fourier rebinning and 2D back projection with Hann filter kernel full-width at half maximum = 3 mm with correction for dead-timer photon attenuation, scatter, and radioactive decay. Brain ß-amyloid deposition was quantified as the ratio of the averaged PiB retention in five bilateral brain regions (anterior cingulate gyrus, frontal cortex, lateral temporal cortex, parietal cortex, and precuneus cortex) to the PiB retention in the cerebellum.

Hippocampal volume and white matter lesion volume were quantified as the proportion of the intracranial volume within the "inner skull" \*10^−2^. Magnetic resonance imaging scans were obtained on a 1.5-T scanner (GE Healthcare, Waukesha, WI) and standard head coil, with fluid-attenuated inversion recovery and 5 ms echo time and 25 ms repetition time. A T1-weighted volumetric spoiled gradient recalled sequence was obtained (0.937 × 0.937 mm) in sagittal (slice thickness = 1.2 mm/0 mm interslice) or coronal plane (slice thickness = 1.5 mm/0 mm interslice).Voxel-based brain morphometry was performed with the sagittal spoiled gradient recalled magnetic resonance imaging acquisition protocol. White matter volumes were quantified by using automatic segmentation software (FMRIB\'s Automated Segmentation Tool [@bib13]; University of Oxford) as described previously using T1-weighted images in native anatomical space [@bib14]. The T2-weighted fluid-attenuated inversion recovery images were used to quantify white matter lesion volume using a fuzzy connectedness algorithm. The intracranial volume was computed with an advanced option (−A) of the Brain Extraction Tool. An atlas-based automated labeling pathway segmentation technique was applied to compute hippocampal volumes using a fully deformable registration procedure to assess preselected regions of interest [@bib15]. Anatomical regions of interest originated from the automated anatomical labeling atlas [@bib16]. The Montreal Neurological Institute Colin 27 average reference brain was transformed to fit each individuals recorded image.

2.4. Covariates {#sec2.4}
---------------

Age, sex, years of education, and race/ethnicity was determined in interviews by trained technicians at the screening visit. Owing to limited variation, race/ethnicity was classified as white and other. At the baseline examination (2000 to 2002), a Health Habits Questionnaire was administered to collect information on smoking status (classified as never, former, and current smoker) and to collect information on alcohol intake (drinks/week). Our analyses used body mass index and systolic blood pressure measured at the study closeout in 2008. For participants with a missing body mass index or blood pressure measurement (N = 133), we replaced the missing value with the value from the closest previous visit (last visit median, 6.4 years after baseline; minimum, 5.5 years; maximum, 7.3 years after baseline examination). *APOE* genotype testing was performed from DNA isolated from baseline blood samples.

At each visit, history of heart disease was assessed in interviews by trained technicians. Participants were asked to bring prescribed medicine and over-the-counter drugs to each clinic visit. Participants were classified as former, current, or never user of antihypertensive and lipid-lowering medications at the last clinic visit.

The neuropsychological examination in 2009 included the administration of the Modified Mini-Mental State Examination [@bib17] and a comprehensive neuropsychological battery of 10 tests evaluating five cognitive domains: (1) memory; (2) visual-spatial construction; (3) language; (4) attention/psychomotor speed; and (5) executive function [@bib18]. A committee of neurologists at the University of Pittsburgh Cognitive Diagnostic Center classified participants as having MCI taking into account cognitive assessments from 2000 to 2009. MCI was defined as 1--3 tests impaired at cutoffs of 1.5 standard deviation below age- and education-adjusted means [@bib19].

2.5. Statistical analysis {#sec2.5}
-------------------------

Age- and sex-adjusted partial correlation coefficients were estimated for pairwise correlations of the biological markers with each other and for the relations of the apolipoproteins to ß-amyloid and hippocampal and white matter lesion volumes. We assessed the cross-sectional associations between apolipoprotein subspecies and amyloid deposition, hippocampal volume, and white matter lesion volume, all from 2009 site visit, in robust linear regression models adjusted for age and sex, education (years), race/ethnicity (white, other), alcohol intake (drinks/week), smoking status (never, former, current), body mass index (kg/m^2^), MCI, history of heart disease, systolic blood pressure, antihypertensive medication use, history of diabetes mellitus, and lipid-lowering medication use. Given the novelty of the apolipoprotein subspecies, no reference values for abnormal levels exist, and we used robust linear regression analysis to prevent that a few influential data points drive associations.

In sensitivity analyses, we examined the association between apolipoprotein subspecies at baseline (2000 to 2002) with the neurobiological endpoints obtained 9 years later. We also performed analyses restricted to participants without MCI and to *APOE* ɛ4 noncarriers.

All analyses were performed using STATA version 12.1 (Stata Corp., College Station, TX).

3. Results {#sec3}
==========

[Table 1](#tbl1){ref-type="table"} shows the characteristics of participants by *APOE* ε4 carriership. None of the *APOE* ɛ4 allele carriers were homozygotes for the E4 allele. *APOE* ε4 allele carriers were slightly more likely to use lipid-lowering or antihypertensive treatment. The prevalence of MCI was similar in *APOE* ε4 carrier and noncarrier. ApoA-I and apoC-III were the most abundant apolipoproteins ([Table 2](#tbl2){ref-type="table"}; [Supplementary Table A.2](#appsec1){ref-type="sec"}). On average, the apolipoproteins tended to be slightly higher in *APOE* ɛ4 allele noncarrier. Most of the apoE was found lacking apoJ, and most of the apoA-I was found lacking apoE, apoJ, or apoC-III.Table 1Characteristics of 176 participants of the GEMS imaging studyCharacteristics[∗](#tbl1fnlowast){ref-type="table-fn"}*APOE* ɛ4 allele noncarrier (N = 119)[†](#tbl1fndagger){ref-type="table-fn"}*APOE* ɛ4 allele carrier (N = 29)Total (N = 176)Sex, male73 (61)15 (52)105 (60)Age, y85 (82, 91)84 (82, 89)85 (82, 91)Education, y14 (10, 19)16 (12, 18)14 (11, 19)Body mass index, kg/m^2^26 (20, 34)25 (20, 30)26 (20, 34)Smoking status[‡](#tbl1fnddagger){ref-type="table-fn"} Never48 (41)13 (45)70 (40) Former67 (57)14 (48)99 (57) Current3 (3)2 (7)6 (3)Alcohol intake[§](#tbl1fnSection){ref-type="table-fn"}, drinks/week0.5 (0, 21)1 (0, 14)0.5 (0, 15)Race, white115 (97)29 (100)170 (97)Total cholesterol, mg/dL167 (107, 241)175 (99, 264)166 (104, 242)HDL cholesterol, mg/dL60 (41, 91)64 (41, 87)60 (39, 91)Triglycerides[‡](#tbl1fnddagger){ref-type="table-fn"}, mg/dL98 (50, 203)96 (39, 241)96 (45, 219)Systolic blood pressure, mm Hg126 (101, 163)122 (105, 164)124 (102, 161)Diastolic blood pressure, mm Hg68 (50, 85)68 (57, 86)67 (51, 84)History of cardiovascular disease42 (35)11 (38)63 (36)History of diabetes[§](#tbl1fnSection){ref-type="table-fn"}6 (5)1 (4)8 (5)Lipid-lowering medication use Never user61 (51)13 (45)87 (49) Former user11 (9)3 (10)18 (10) Current use47 (40)13 (45)71 (40)Antihypertensive treatment Never user35 (29)8 (28)52 (30) Former user4 (3)1 (3)6 (3) Current use80 (67)20 (69)118 (67)Mild cognitive impairment26 (22)7 (24)39 (22)3MSE98 (90, 100)98 (91, 100)98 (90, 100)ß-amyloid deposition, SUVR1.6 (1.2, 2.6)2.1 (1.2, 2.8)1.6 (1.2, 2.6)Hippocampal volume[¶](#tbl1fnpara){ref-type="table-fn"}, % of ICV26 (21, 31)25 (20, 32)26 (20, 31)White matter lesion volume[¶](#tbl1fnpara){ref-type="table-fn"}, % of ICV0.7 (0.2, 2.1)0.7 (0.3, 2.5)0.8 (0.2, 2.3)[^1][^2][^3][^4][^5][^6]Table 2Apolipoprotein and apolipoprotein subspecies distributions by *APOE* ɛ4 allele carrier status in 148 participants of the GEMS imaging study in 2008Apolipoprotein concentrations,[∗](#tbl2fnlowast){ref-type="table-fn"} mg/dL*APOE* ɛ4 allele noncarrier (N = 119)*APOE* ɛ4 allele carrier (N = 29)In whole plasma− ApoE9.0 (4.9, 16.6)8.4 (3.6, 13.0) ApoJ5.5 (4.4, 6.7)5.5 (4.3, 6.9) ApoA-I152 (93, 235)160 (102, 246) ApoC-III12.5 (6.0, 22.7)14.1 (7.5, 23.8)In HDL fraction of plasma[†](#tbl2fndagger){ref-type="table-fn"} ApoE6.1 (3.2, 11.3)5.4 (2.3, 10.2) ApoE containing apoJ0.2 (0.1, 0.4)0.2 (0.1, 0.4) ApoE lacking apoJ5.9 (3.1, 11.0)5.3 (2.2, 9.9) Proportion of apoE containing apoJ, %3.9 (2.2, 8.6)3.9 (2.2, 7.2) ApoE containing apoC-III[‡](#tbl2fnddagger){ref-type="table-fn"}3.0 (1.3, 6.1)2.5 (1.0, 6.3) ApoE lacking apoC-III[‡](#tbl2fnddagger){ref-type="table-fn"}2.9 (0.5, 7.3)2.5 (1.0, 6.4) Proportion of apoE containing apoC-III,[‡](#tbl2fnddagger){ref-type="table-fn"} %51 (26, 90)46 (18, 76) ApoA-I containing apoE12.1 (4.5, 42.5)10.1 (4.0, 20.3) ApoA-I lacking apoE138 (82, 213)151 (99, 237) Proportion of apoA-I containing apoE, %7.8 (3.4, 19.7)6.2 (2.4, 10.8) ApoA-I containing apoJ2.1 (1.0, 3.1)2.3 (1.4, 3.5) ApoA-I lacking apoJ150 (92, 231)158 (101, 243) Proportion of apoA-I containing apoJ, %1.3 (0.9, 2.1)1.3 (1.1, 2.0) ApoA-I containing apoC-III9.3 (3.6, 19.2)10.2 (3.9, 22.3) ApoA-I lacking apoC-III141 (83, 222)150 (98, 238) Proportion of apoA-I containing apoC-III, %6.0 (3.0, 11.8)6.5 (3.3, 12.6) ApoC-III8.7 (3.6, 14.7)10.2 (4.1, 15.5)[^7][^8][^9][^10]

The age- and sex-adjusted correlation of ß-amyloid and hippocampal volume was, as expected, inverse (r = −0.17, *P* = .03). White matter lesion volume was not correlated to ß-amyloid or hippocampal volume (r = −0.02, *P* = .80, and r = 0.04, *P* = .64, respectively).

In age- and sex-adjusted models, higher apoE in whole plasma and higher apoE in HDL fraction of plasma were statistically significantly associated with lower ß-amyloid deposition ([Supplementary Table A.3](#appsec1){ref-type="sec"}). Furthermore, the subspecies of apoE lacking apoC-III and the subspecies of apoA-I containing apoE were related inversely to ß-amyloid deposition. Associations persisted after multivariable adjustment and were generally strengthened ([Table 3](#tbl3){ref-type="table"}). Multivariable adjustment revealed apoE subspecies lacking apoJ and apoE containing or lacking apoC-III statistically significantly inversely related to ß-amyloid deposition.Table 3Mean difference (95% CI)[∗](#tbl3fnlowast){ref-type="table-fn"} in ß-amyloid, hippocampal volume, and white matter lesion volume per 1 SD higher apolipoprotein concentration in 171 participants of the GEMS imaging study in 2009ExposureMultivariable adjusted mean differences (95% CI)ß-amyloid deposition SUVR (N = 171)Hippocampal volume, % of ICV (N = 152)White matter lesion volume, % of ICV (N = 152)Age, years0.01 (−0.02, 0.03)−0.20 (−0.40, 0.01)**0.07 (0.04, 0.10)***APOE* ɛ4 allele carrier versus noncarrier**0.32 (0.13, 0.52)**[†](#tbl3fndagger){ref-type="table-fn"}−0.23 (−1.59, 1.14)[‡](#tbl3fnddagger){ref-type="table-fn"}0.05 (−0.23, 0.32)[‡](#tbl3fnddagger){ref-type="table-fn"}Whole plasma ApoE−**0.12 (−0.19, −0.06)**0.48 (−0.12, 1.08)0.04 (−0.03, 0.11) ApoJ−0.01 (−0.09, 0.06)**0.59 (0.08, 1.11)**0.05 (−0.02, 0.12) ApoA-I−0.01 (−0.08, 0.06)0.36 (−0.12, 0.84)0.07 (−0.03, 0.16) ApoC-III−0.02 (−0.10, 0.06)0.03 (−0.65, 0.71)\<−0.01 (−0.10, 0.10)HDL fraction of plasma[§](#tbl3fnSection){ref-type="table-fn"} ApoE**−0.12 (−0.18, −0.06)**0.32 (−0.31, 0.94)0.08 (−0.01, 0.16) ApoE containing apoJ−0.07 (−0.15, 0.01)−0.33 (−1.05, 0.38)−0.06 (−0.17, 0.05) ApoE lacking apoJ**−0.09 (−0.16, −0.02)**0.42 (−0.26, 1.11)**0.10 (0.01, 0.18)** ApoE containing apoC-III**−0.10 (−0.17, −0.02)**[¶](#tbl3fnpara){ref-type="table-fn"}−0.23 (−0.81, 0.35)[‖](#tbl3fnVerbar){ref-type="table-fn"}0.06 (−0.03, 0.16)[‖](#tbl3fnVerbar){ref-type="table-fn"} ApoE lacking apoC-III**−0.09 (−0.15, −0.03)**[¶](#tbl3fnpara){ref-type="table-fn"}0.63 (−0.06, 1.32)[‖](#tbl3fnVerbar){ref-type="table-fn"}0.02 (−0.07, 0.12)[‖](#tbl3fnVerbar){ref-type="table-fn"} ApoA-I containing apoE**−0.12 (−0.19, −0.05)**−0.17 (−0.65, 0.31)0.03 (−0.06, 0.11) ApoA-I lacking apoE0.05 (−0.02, 0.12)0.45 (−0.06, 0.96)0.05 (−0.05, 0.16) ApoA-I containing apoJ0.03 (−0.06, 0.12)**−0.72 (−1.31, −0.13)**0.03 (−0.08, 0.14) ApoA-I lacking apoJ−0.02 (−0.11, 0.06)**0.84 (0.23, 1.45)**0.05 (−0.08, 0.18) ApoA-I containing apoC-III0.01 (−0.06, 0.08)**−0.39 (−0.72, −0.05)**−0.04 (−0.13, 0.05) ApoA-I lacking apoC-III−0.01 (−0.09, 0.06)**0.50 (0.01, 0.98)**0.08 (−0.02, 0.18) ApoC-III−0.02 (−0.09, 0.06)0.23 (−0.41, 0.88)0.02 (−0.08, 0.13)[^11][^12][^13][^14][^15][^16][^17][^18]

In multivariable adjusted models, participants with higher concentrations of apoJ had higher hippocampal volume ([Table 3](#tbl3){ref-type="table"}). Although apoA-I in whole plasma was unrelated to hippocampal volume, there were differential associations of hippocampal volume with the subspecies apoA-I containing or not containing apoJ (mean difference per 1 standard deviation (SD) higher apoA-I containing apoJ: −0.72% \[95% confidence interval (CI): −1.31 to −0.13\] and mean difference per 1 SD higher apoA-I not containing apoJ: 0.84% \[95% CI: 0.23--1.45\]); the subspecies of apoA-I coexisting or not containing apoC-III (mean difference per 1 SD higher apoA-I containing apoC-III: −0.39% \[95% CI: −0.72 to −0.05\] and mean difference per 1 SD higher apoA-I not containing apoC-III: 0.50% \[95% CI: 0.01--0.98\]). For comparison, a difference of 0.60% lower hippocampal volume was approximately equivalent to the difference in hippocampal volume associated with a 3-year older age (mean difference per 1-year higher age: −0.20% \[95% CI: −0.40 to 0.01\]).

ApoE lacking apoJ was related to higher white matter lesion volume in multivariable adjusted regression models ([Table 3](#tbl3){ref-type="table"}) (mean difference per 1 SD higher apoE lacking apoJ: 0.10% \[95% CI: 0.01--0.18\]). All other apolipoproteins and apolipoprotein subspecies were not statistically significantly associated with white matter lesion volume.

In a subset of participants, we were able to differentiate apoE containing or lacking apoA-I ([Supplementary Table A.2](#appsec1){ref-type="sec"}). Most of the apoE was found containing apoA-I. ApoE containing or lacking apoA-I was not statistically significantly related to ß-amyloid deposition, hippocampal volume, or white matter lesion volume in multivariable adjusted regression models.

We determined the long-term association of apolipoproteins and the imaging markers of Alzheimer\'s pathophysiology using apolipoprotein measures obtained at the baseline visit from 2000 to 2002 ([Supplementary Table A.4](#appsec1){ref-type="sec"}). The same correlation patterns with ß-amyloid deposition were observed for the apolipoproteins assessed at baseline as analyzed at the closeout in 2008. However, apolipoproteins at the baseline visit did not correlate with hippocampal volume or white matter lesion volume.

When we restricted the study population to participants without MCI and *APOE* ε4 noncarriers, associations between the apolipoproteins and the imaging outcomes were very similar in direction and magnitude compared to the overall analysis ([Supplementary Table A.5](#appsec1){ref-type="sec"}).

4. Discussion {#sec4}
=============

In this selected sample of elderly participants without dementia, overall plasma apoE, apoE in HDL, and subspecies of apoE and apoA-I were associated with structural and functional neuroimaging parameters. Higher hippocampal volumes were found in participants with higher apoJ concentrations. The relation was generally similar after excluding participants with MCI or *APOE* ε4 allele carrier. These results highlight the potential importance of apolipoprotein subspecies in understanding the pathogenesis of AD.

Given the very strong associations of allelic differences in genes encoding apolipoproteins with risk of AD [@bib2], [@bib20], it is perhaps surprising that few studies have assessed the associations of apolipoproteins in the circulation with ß-amyloid deposition and neurodegeneration. Those that have done so have reported largely inconsistent findings. ApoE has been proposed to play key roles in the regulation of neurotoxic ß-amyloid peptide levels in the brain by limiting its deposition and increasing its clearance [@bib21], [@bib22], [@bib23]. ApoE also protects the microtubule-associated protein tau from hyperphosphorylation [@bib21], [@bib23], [@bib24]. Our finding of an inverse association of circulating apoE with brain ß-amyloid deposition agrees with recent cross-sectional, age- and sex-adjusted data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing [@bib25]. Although the Baltimore Longitudinal Study of Aging (BLSA) suggested that circulating apoE levels are positively associated with ß-amyloid accumulation in the medial temporal cortex of nondemented elderly participants, the sample size of 42 participants was substantially lower than that in our study, and study participants were younger [@bib26]. Given the nonoverlapping age range in the BLSA and our study, we cannot exclude that the association of apoE with Alzheimer\'s pathology differs at different age periods or at different stages of the Alzheimer\'s pathology continuum. Associations of apoE and AD pathology might also differ by apoE isoforms. Martínez-Morillo observed no association between total plasma apoE and apoE isoforms with biomarkers of AD including total tau, phosphorylated tau, or amyloid beta 1--42 [@bib27]. In contrast, the Australian Imaging, Biomarkers and Lifestyle study found similar associations for total plasma apoE and apoE ɛ4 isoform concentrations with ß-amyloid deposition [@bib28]. Future studies on apoE subspecies considering apoE isoforms are important future research avenues.

Given that findings on apoE in the circulation and neurodegeneration have been inconsistent [@bib29], [@bib30], [@bib31], [@bib32], our findings that apoE subspecies lacking apoJ might be more closely related to white matter lesion volume than total apoE concentration support further investigation of apoE subspecies in relation to AD risk. Because circulatory and brain apoE pools are distinct [@bib33] and plasma and CSF concentrations tend to correlate poorly [@bib27], plasma apoE has been hypothesized to impact ß-amyloid deposition and neurodegeneration indirectly, by protecting blood brain barrier integrity and cerebrovascular function [@bib34].

In our study, plasma apoJ and apoC-III concentrations were unrelated to neuroimaging parameters with the exception of an association of apoJ with hippocampal volume. In 60 dementia-free participants from the BLSA, plasma apoJ concentration 10 years before PET correlated positively with ß-amyloid deposition taking age and sex into account [@bib35]. However, the baseline circulating apoJ concentrations were not related to changes in hippocampal volume over 6 years of follow-up in the BLSA [@bib36]. In the Australian Imaging, Biomarkers and Lifestyle study, plasma apoJ also correlated directly with ß-amyloid deposition assessed by positron emission tomography and inversely with hippocampal volume in the combined study sample which included participants with normal cognition, MCI, or AD [@bib37]. At this juncture, particularly given the low concentrations of apoJ found in plasma, we view overall results as still inconclusive. Despite some evidence that apoC-III can bind circulatory ß-amyloid, our understanding of the relationship of apoC-III and AD pathology is limited [@bib38]. ApoC-III levels were unrelated to hippocampal volume in age- and sex-adjusted analyses of the Sydney Memory and Aging Study [@bib30]. Further studies of apoJ and apoC-III and neuropathology with repeated imaging are needed to clarify their roles in AD pathology.

We found no evidence that plasma apoA-I was associated with brain amyloid deposition, hippocampal volume, or white matter lesion volume. In vitro experimental studies have shown that human apoA-I can bind amyloid β, and prevents amyloid aggregation as well as amyloid β--induced neuronal damage to hippocampal cultures [@bib39]. Mice that overexpress human apoA-I have similar amounts of Aβ in the brain compared with control mice but have less cerebral amyloid angiopathy, suggesting selective effects of apoA-I on vascular amyloid deposition [@bib40]. In our study, the resolution of the PET images did not allow distinction between parenchymal and vascular amyloid burden.

When we separated apoA-I in subspecies containing or lacking apoJ or apoC-III, the concentration of apoA-I containing apoJ and apoC-III was inversely related to hippocampal volume. These subspecies could be functionally more relevant than overall apoA-I concentration, or they could be markers for specific brain apolipoproteins. Recently, we reported that that the CSF concentration of apoC-III might be better approximated by plasma apoA-I containing apoC-III than total plasma apoC-III. Similarly, CSF apoJ correlated most strongly with apoA-I lacking apoJ [@bib10]. Together, these results suggest that the relation of apoA-I and hippocampal volume is likely more complex and warrants further study [@bib41]. A previous cross-sectional study in 1282 middle-aged and elderly study participants found an inverse association between apoA-I concentration and white matter lesion volume, which was not replicated in our study possibly because of smaller sample size and the special nature of this study population free of clinical dementia around the age of 85 years [@bib42].

There were some specific limitations of this study. The study sample was a highly selective sample of oldest old, dementia-free survivors---limiting the generalizability to younger populations. None of the study participants were homozygotes for the *APOE* ɛ4 allele, and we had limited statistical power to investigate associations by *APOE* genotype. Thus, additional studies are needed to further confirm these associations and to test if associations differ by *APOE* isoforms. No CSF samples were available, and plasma and CSF lipoproteins differ in composition and metabolism. We precipitated for apoB-containing lipoproteins to narrow our investigations to lipoproteins in the range of densities found in the central nervous system. HDL-like particles found in the brain contain apoE along with apoA-I, but no apoB [@bib43]. Nevertheless, CSF biomarkers are of limited use in large-scale studies and in routine clinical practice, and enormous interest in the identification of blood markers related to AD exists. It is a limitation of our study that we do not formally test whether the different apolipoproteins are present on separate lipoprotein particles or if they are bound to each other and carry phospholipid for the constellation of a lipoprotein. Strength of this study is the uniquely detailed assessment of neurological status and the assessment of an unprecedented variety of apolipoproteins and their subspecies as well as the comprehensive control for potential confounders.

5. Conclusion {#sec5}
=============

In this selective sample of elderly participants lacking dementia, overall apoE concentrations were associated with AD pathology. Subspecies of apoE and apoA-I were differentially associated with neuropathology. The relations were generally similar after excluding participants with MCI or *APOE* ε4 carrier. Given the observed differential associations of apolipoproteins and their subspecies, further study of these in relation to AD pathology in younger populations and in relation to AD and cognitive decline in larger prospective samples is needed.Research in Context1.Systematic review: PubMed search identified several genome-wide association studies that linked genetic variation in regions that encode apolipoproteins, including apoE, apoJ, apoC-III, and apoA-I, to Alzheimer\'s disease and few studies examining plasma concentrations of apolipoproteins and Alzheimer\'s disease.2.Interpretation: Apolipoproteins may be important minimally invasive biomarkers indicative of Alzheimer\'s pathology. Subspecies of apoA-I containing either apoJ or apoC-III might be more closely related to hippocampal volume than overall apoA-I.3.Future directions: Given the observed differential associations of apolipoproteins and their subspecies, further study of these in relation to Alzheimer\'s disease pathology in younger populations and in relation to Alzheimer\'s disease and cognitive decline in larger prospective samples is needed.
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[^1]: Abbreviations: ICV, intracranial volume; 3MSE, Modified Mini-Mental State Examination score; SUVR, standardized uptake value ratio; HDLs, high-density lipoproteins; GEMS, Ginkgo Evaluation of Memory Study; *APOE*, apolipoproteins E.

[^2]: Values are median (Q5, Q95) or n (%).

[^3]: N = 28 individuals with missing *APOE* genotype information were excluded.

[^4]: N = 175.

[^5]: N = 174.

[^6]: N = 157.

[^7]: Abbreviations: HDL, high-density lipoproteins; GEMS, Ginkgo Evaluation of Memory Study; *APOE*, apolipoproteins E; apo, apolipoproteins.

[^8]: Values are median (Q5, Q95).

[^9]: Plasma precipitated of apoB-containing lipoproteins.

[^10]: N = 133.

[^11]: Abbreviations: ICV, intracranial volume; SUVR, standardized uptake value ratio; HDLs, high-density lipoproteins; GEMS, Ginkgo Evaluation of Memory Study.

[^12]: NOTE. Statistically significant differences are highlighted in bold.

[^13]: Each lipoprotein was modeled separately. Subspecies of a lipoprotein containing or not containing a given apolipoprotein sum to the total for that lipoprotein, and thus, all models simultaneously include the two subspecies. Models were adjusted for age, sex, education (years), race/ethnicity (white, other), alcohol intake (drinks/week), smoking status (never, former, current), body mass index (kg/m^2^), mild cognitive impairment, history of heart disease, systolic blood pressure, antihypertensive medication use, history of diabetes mellitus, and lipid-lowering medication use.

[^14]: N = 144.

[^15]: N = 127.

[^16]: Plasma precipitated of apoB-containing lipoproteins.

[^17]: N = 151.

[^18]: N = 136.
